Isotype Switching

The Fc portion of an antibody determines the isotype of the, molecule and confers effector functions such as antibody-dependent cellular cytotoxicity (ADCC). In most cases it is desirable to for therapeutic antibodies to lack Fc effector functions such as ADCC. We have a human IgG4 Fc that lacks the binding site for Fc gamma receptor engagement and is therefore immunologically ‘silent’ in this regard.

Process:
  • Sequencing of the VH and VL genes
  • Humanization (if human antibody is required)
  • Synthesis and cloning of VH and VL genes into expression vector for production of full-length immunoglobulin with desired Fc
  • Transfection and expression of antibody in CHO cells
  • Antibody purification
  • Test antibody binding to antigen, (ELISA or SPR), and/or ADCC activity in vitro
  • Detailed report
Timeline:
  • ~12 weeks from reception of the VH and VL sequences